Clinical Trials Logo

Prediabetic State clinical trials

View clinical trials related to Prediabetic State.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06119035 Completed - PreDiabetes Clinical Trials

Insulin Modelling Based on Plasma Glucose Measures Via a Minimally-Invasive Glucose Sensor

Start date: November 6, 2023
Phase: N/A
Study type: Interventional

The study aims to evaluate insulin as a potential biomarker for prediabetes in Singapore Chinese subjects.

NCT ID: NCT06064058 Completed - Diabetes Clinical Trials

Assessing the Effects of HbA1c Reduction on Alleviating Nonspecific Back Pain

Start date: January 30, 2023
Phase: N/A
Study type: Interventional

Prediabetes, characterized by elevated HbA1c levels, is a common precursor to type 2 diabetes mellitus. Recent studies have suggested a potential link between prediabetes and nonspecific back pain. This randomized controlled trial aimed to assess whether reducing HbA1c levels through lifestyle interventions and, along with the correction of vitamin D and magnesium, can alleviate nonspecific back pain in prediabetic patients.

NCT ID: NCT05990205 Completed - PreDiabetes Clinical Trials

Effect of the SCL16A11 Risk Haplotype on Treatments to Prevent Type 2 Diabetes

PRED2
Start date: April 17, 2018
Phase: Phase 2
Study type: Interventional

The goal of this randomized clinical trial is to determine the impact of the risk haplotype on SLC16A11 on early therapeutic responses in treatments to prevent T2D in Mexican mestizos with prediabetes. The main question[s] it aims to answer are: - Evaluate the effect of the risk haplotype on weigth loss >3% - Evualuate the differences in lipid profiles and glycemic parameters (fasting glucose, HbA1c). Participants will be randomized into two groups: lifestyle intervention (LSI): hypocaloric diet, 25 kcal/kg of ideal weight, 45% of the total intake of carbohydrates, 30% lipids, and 25% protein sources + physical activity (>150 min medium intensity per week), or LSI + MET (750 mg metformin twice a day). Researchers will compare carriers and non carriers of the risk haplotype of SLC16A11 to see if there are diferent treatment responses.

NCT ID: NCT05869344 Completed - PreDiabetes Clinical Trials

Black Bean (Phaseolus Vulgaris L.) Protein Hydrolysates Reduce Acute Postprandial Glucose Levels

Start date: October 15, 2018
Phase: N/A
Study type: Interventional

This work aimed to evaluate the acute effect of a black bean protein hydrolysate (BPH) on glucose levels in adults with normal glucose tolerance (NGT) and prediabetes. Twenty peptides were identified in BPH, and a followed in silico predictive digestion showed a release of several short-chain peptides with potential hypoglycemic potential. A double-blind, placebo-controlled, randomized clinical trial was conducted on 28 adults with NGT or prediabetes. After consent, participants were randomized into two groups, placebo or the corresponding 5 g BPH treatment. An oral glucose tolerance test (OGTT) (75 g glucose) was used to measure glucose tolerance before treatment. A second OGTT was used to evaluate the acute effect of the BPH, and blood samples were collected at 0, 60, 120, and 150 min, and blood glucose levels were measured.

NCT ID: NCT05822648 Completed - Type 2 Diabetes Clinical Trials

Evaluating a Type 2 Diabetes Prevention Program

Start date: April 15, 2023
Phase: N/A
Study type: Interventional

This study aims to test the effectiveness of a Type 2 Diabetes (T2D) prevention program for individuals who have been diagnosed with prediabetes compared to a T2D educational control group. Project health is an obesity prevention program and has produced a 42% to 53% reduction in future onset of overweight/obesity and also produced greater reductions in negative affect compared to assessment-only controls that persisted. Project Health has been adapted to prevent onset of T2D among individuals with prediabetes. The study aims to test the effectiveness of Project Health at reducing BMI, HbA1c levels, increase physical activity and improve glucose control.

NCT ID: NCT05759442 Completed - PreDiabetes Clinical Trials

Clinical Efficacy and Safety of Metformin Versus Apple Cider Vinegar (ACV) in Prediabetics

BUHSCK
Start date: January 1, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to compare efficacy and safety of metformin versus apple cider vinegar in prediabetics . The main question[s] it aims to answer are: - Efficacy of metformin versus apple cider vinegar in prediabetics - Safety of metformin versus apple cider vinegar in prediabetics Researchers will compare group of prediabetics taking metformin with group of prediabetics taking apple cider vinegar to see if there is difference in safety and efficacy..

NCT ID: NCT05695170 Completed - Clinical trials for Overweight and Obesity

Couple-Based Lifestyle Intervention to Prevent Type 2 Diabetes

Start date: December 14, 2022
Phase: N/A
Study type: Interventional

The goal of this randomized pilot clinical trial is to describe the feasibility of a couple-based lifestyle intervention and the study protocol in preparation for a future definitive randomized clinical trial. Participants include individuals at risk for type 2 diabetes and their romantic partners. The main objectives are: 1. To describe the feasibility of the couple-based intervention. 2. To describe the feasibility of the study protocol for use in a definitive trial. Participating couples will be randomized to one of two year-long lifestyle intervention conditions: an individual curriculum or a couple-based curriculum. Participants will complete assessments before and after the year-long intervention, as well as monthly during the intervention. Data will be collected on: feasibility, background, health behaviors, physical and mental health, and relationship functioning.

NCT ID: NCT05689658 Completed - PreDiabetes Clinical Trials

Brazilian Diabetes Prevention Program: Pilot Study

PROVEN-Dia
Start date: March 15, 2023
Phase: N/A
Study type: Interventional

To structure a Brazilian Diabetes Prevention Program based on guidance for changing lifestyle promoted by the American Diabetes Prevention Program, using materials already developed by the Brazilian Ministry of Health and contextualizing it to the Brazilian Public Health System (SUS) and evaluating its effectiveness in a multicentric randomized clinical trial with 220 pre-diabetic patients and a follow up of 3 months. Outcomes are diet quality and time of physical activity. Health care professionals' perceptions regarding its incorporation into clinical practice will also be evaluated.

NCT ID: NCT05654727 Completed - Clinical trials for Cognitive Impairment

Cognitive Functions and BDNF in T2DM and Prediabetes Patients

Start date: July 1, 2021
Phase:
Study type: Observational

Clinical and epidemiological studies suggest links between cognitive impairments and Type 2 diabetes (T2DM). The underlying mechanisms and causality in diabetes-related cognitive impairment are largely unknown. The aim of this study is to investigate cognitive impairment and the role of BDNF in prediabetes and diabetes patients.

NCT ID: NCT05628597 Completed - Pre Diabetes Clinical Trials

Effects of Fos Biomedical Device on Diabetes Risk Factors and Sleep Quality in Adults at Risk for Type 2 Diabetes

Start date: November 23, 2021
Phase: N/A
Study type: Interventional

Purpose Phototherapy has an array of potential benefits in human health. The effects of a non-transdermal Fos Biomedical product (which utilizes the concept of phototherapy) on diabetes risk factors and sleep quality in people at risk for type 2 diabetes are unclear. Proposed is a single-blind randomized crossover placebo-controlled trial to assess the impact of daily use of the Fos Biomedical product for a 12-week period on cardio-metabolic risk factors and self-reported sleep quality among adults at risk for type 2 diabetes. Specific Aims - To determine the effects of the use of the Fos Biomedical product daily for 12 weeks, as compared to placebo patch, on glycemic control in adults at risk for type 2 diabetes. Specifically, to show that the use of the Fos Biomedical product for 12 weeks, as compared to placebo patch, will improve glycated hemoglobin in adults at risk for type 2 diabetes. - To assess the effects of the use of the Fos Biomedical product, versus placebo patch, for a 12-week period on insulin sensitivity, serum lipids, C-reactive protein, anthropometric measures, self-reported sleep quality, and endothelial function in adults at risk for type 2 diabetes. Specifically, to show clinically meaningful improvement or neutral effects in insulin sensitivity, serum lipids, C-reactive protein, anthropometric measures, self-reported sleep quality, and endothelial function in adults at risk for type 2 diabetes. - To assess the impact of Fos Biomedical product on liver function and kidney function in adults at risk for type 2 diabetes Hypotheses - Daily use of the Fos Biomedical product for 12 weeks will improve glycated hemoglobin in adults at risk for type 2 diabetes. - Daily use of the Fos Biomedical product for 12 weeks will improve or have neutral effects on insulin sensitivity, serum lipids, C-reactive protein, anthropometric measures, self-reported sleep quality and endothelial function in adults at risk for type 2 diabetes. - The use of the Fos Biomedical product will have no clinically meaningful adverse effects on liver function and kidney function in adults at risk for type 2 diabetes.